CHMP recommends EU approval of Roche’s subcutaneous Herceptin for HER2 positive breast cancer
28 June 2013 | By Roche
"Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer..."
List view / Grid view
28 June 2013 | By Roche
"Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer..."
24 September 2012 | By
Data on 13 of its investigational and approved products will be presented at ESMO 2012...
19 October 2011 | By Richard Morgan, Postgraduate Medical School, Faculty of Health and Medical Sciences, University of Surrey
The HOX genes are a family of closely related transcription factors that help to define the identity of cells and tissues during embryonic development and which are also frequently deregulated in cancer, where they have been shown to promote cell survival and proliferation. The high level of cancer-associated HOX expression…
30 August 2011 | By Boehringer Ingelheim
Two phase II studies investigating afatinib are now open for recruitment...
5 July 2011 | By Novartis AG
Afinitor® in combination with exemestane extended progression-free survival in women with advanced breast cancer...
13 May 2011 | By European Pharmaceutical Review
Pfizer will settle more than 2,200 lawsuits alleging the company's Wyeth unit hid Prempro's cancer risks...